Compare Abeona Therapeutics Inc (ABEO) vs Cintas Corporation (CTAS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Cintas Corporation — how do they compare? Abeona Therapeutics Inc trades at $6.77 (market cap $373.32M), while Cintas Corporation trades at $181.34 (market cap $72.76B). The key difference: Cintas Corporation is far larger — about 194.9× Abeona Therapeutics Inc's market cap, and Cintas Corporation pays a 0.99% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | CTAS | |
|---|---|---|
Market Cap | $373.32M | $72.76B |
Sector | Health | Industrials |
52-Week High | $7.23 | $226.27 |
52-Week Low | $4.17 | $163.55 |
Enterprise Value | $228.22M | $75.49B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
CTAS trades at $181.83, up 0.29% with a bullish technical signal. The stock shows strong fundamentals with revenue growing from $7.9B in 2022 to $10.3B in 2025 and net income margins expanding to 17.57%. Recent earnings mostly beat expectations, and the company maintains a 43-year dividend growth streak. Positive sentiment is supported by analyst coverage and recent corporate recognitions.
Outlook remains positive with a consensus price target of $212.50, implying 17% upside. Risks include elevated valuation multiples (P/E 37.6) and integration challenges from the UniFirst acquisition. The stock offers growth and income appeal but requires monitoring of execution and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →
